Sanofi Logo
CAD Logo


Support in your corner with ENJAYMO patient solutions
ENJAYMO Patient Solutions is here to help support you through your treatment journey. We're available to assist you Monday through Friday, 8 AM to 8 PM ET, at 1-833-223-2428.
Meet the team that’s ready to support you
When you enroll in ENJAYMO Patient Solutions, you gain access to a dedicated team that can connect you with education and a range of resources on ENJAYMO.
Case Managers
Case managers are experienced in helping individuals get started on treatment and assisting with insurance‑related needs. They are also an ongoing resource should you need additional support along the way.
Therapeutic education managers (TEMS)
Therapeutic Education Managers, or TEMs, are available to provide education about ENJAYMO and CAD. TEMs help raise awareness about CAD in the community and educate patients and caregivers. They engage with patients to provide information and facilitate educational events about ENJAYMO and CAD. Talk to your Case Manager to learn more about how to contact a TEM.
TEMs are paid to provide educational services on behalf of Sanofi. They do not provide medical advice. You should always talk to your doctor about any healthcare needs.
Enjaymo patient solutions
The ENJAYMO Patient Solutions Financial Assistance Programs are designed to provide support for eligible patients who wouldn't be able to access ENJAYMO otherwise. There are two options available:
Copay assistance program
The ENJAYMO Copay Assistance Program may be able to help with eligible patients’ treatment costs, such as out-of-pocket, co-payments or co-insurance, and cost of infusion, if they meet the program requirements.*
The Patient assistance program
ENJAYMO Patient Assistance Program provides financial support for eligible patients who have limited access to treatment due to insurance issues and financial challenges.
The ENJAYMO Patient Solutions Copay Program (the “Program”) is not valid for prescriptions covered, in whole or in part, under Medicare, Medicaid, VA, DoD, TRICARE® or similar federal or state programs, including any state pharmaceutical assistance programs. The Program is not valid where prohibited by law, and savings may vary depending on patients’ out-of-pocket costs. Sanofi reserves the right to modify or terminate the Program at any time without notice. Patient’s Copay benefit not to exceed annual maximum savings of $25,000. Patients will receive all Program details upon registration.
IMPORTANT NOTICE: Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, or any state pharmaceutical assistance program, etc. to pay in part or in full for their ENJAYMO prescription. Not valid where prohibited by law. Savings by patients may vary depending on their out-of-pocket and infusion costs.
Find free in-person and online educational events to learn more about CAD and ENJAYMO.
ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.
Do not receive ENJAYMO if you are allergic to sutimlimab-jome or any of the ingredients in ENJAYMO.
ENJAYMO can cause serious side effects, including:
Serious Infections: ENJAYMO is a prescription medicine that affects your immune system. ENJAYMO may lower the ability of your immune system to fight infections. ENJAYMO increases your chance of getting serious infections including those caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. These serious infections may quickly become life-threatening or cause death if not recognized and treated early.
You must complete or be up to date with the vaccines against Streptococcus pneumoniae and Neisseria meningitidis at least 2 weeks before your first dose of ENJAYMO.
If your healthcare provider decides that urgent treatment with ENJAYMO is needed, you should receive vaccinations as soon as possible.
If you have been vaccinated against these bacteria in the past, you might need additional vaccines before starting ENJAYMO. Your healthcare provider will decide if you need additional vaccines.
Vaccines do not prevent all infections caused by encapsulated bacteria. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a serious infection:
fever with or without shivers or chills
fever and a rash
fever with chest pain and cough
fever with breathlessness or fast breathing
fever with high heart rate
headache with nausea or vomiting
headache and fever
headache with stiff neck or stiff back
body aches with flu-like symptoms
clammy skin
eyes sensitive to light
Infusion-related reactions: Treatment with ENJAYMO may cause infusion-related reactions, including allergic reactions that may be serious or life-threatening. Your healthcare provider may slow down or stop your ENJAYMO infusion if you have an infusion-related reaction and will treat your symptoms if needed. Tell your healthcare provider right away if you develop symptoms during your ENJAYMO infusion that may mean you are having an infusion-related reaction, including:
shortness of breath
decrease in blood pressure
injection site reaction
chest discomfort
itchy skin
rapid heartbeat
Risk of autoimmune disease: ENJAYMO may increase your risk for developing an autoimmune disease such as systemic lupus erythematosus (SLE). Tell your healthcare provider and get medical help if you develop any symptoms of SLE, including:
joint pain or swelling
rash on the cheeks and nose
unexplained fever
If you have CAD and you stop receiving ENJAYMO, your healthcare provider should monitor you closely for the return of your symptoms after you stop ENJAYMO. Stopping ENJAYMO may cause the breakdown of your red blood cells due to CAD return. Symptoms or problems that can happen due to red blood cell breakdown include:
Rapid heart rate
Shortness of breath
Blood in your urine or dark urine
The most common side effects of ENJAYMO include:
increase in blood pressure
joint pain
urinary tract infection
feeling tired or weak
respiratory tract infection
bacterial infection
runny nose
swelling in lower legs or hands
bluish color to the lips and skin
changes in color or sensation in the fingers and toes (Raynaud's phenomenon)
These are not all the possible side effects of ENJAYMO. Call your doctor for medical advice about side effects.
Before receiving ENJAYMO, tell your healthcare provider about all of your medical conditions, including if you:
have a fever or infection, including a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
have an autoimmune disease such as systemic lupus erythematosus (SLE), also known as lupus.
are pregnant or plan to become pregnant. It is not known if ENJAYMO will harm your unborn baby.
are breastfeeding or plan to breastfeed. It is not known if ENJAYMO passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
ENJAYMO® is a prescription medicine used to treat the breakdown of red blood cells (hemolysis) in adults with cold agglutinin disease (CAD).

It is not known if ENJAYMO is safe and effective in children.
Back to the top